迪哲医药: 迪哲医药：北京市中伦律师事务所关于迪哲（江苏）医药股份有限公司2024年年度股东大会的法律意见书

Core Points - The legal opinion letter confirms the legality of the 2024 annual general meeting of Dize (Jiangsu) Pharmaceutical Co., Ltd. [1][16] - The opinion is based on the review of relevant laws, regulations, and the company's articles of association [1][2] Group 1: Meeting Procedures - The notice for the 2024 annual general meeting was properly communicated to all shareholders, including details on time, location, and agenda [3][4] - The meeting was convened in accordance with the relevant legal and regulatory requirements [4][15] Group 2: Attendance and Qualifications - A total of 9 shareholders and their proxies attended the meeting, representing 178,558,990 shares, which is 38.87% of the total voting shares [4][6] - The qualifications of the attendees were verified, confirming their legitimacy to participate in the meeting [4][6] Group 3: Voting Procedures and Results - Voting was conducted through both on-site and online methods, with results being monitored and counted by designated personnel [6][15] - The voting results showed that 295,693,967 shares were in favor of the proposals, representing a significant majority of the votes cast [7][14]